-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
During the 3rd China International Import Expo, Wang Hui, head of the AIDS Medical Center of the Third People's Hospital of Shenzhen, and Xu Ding, head of GSK China's core prescription drugs and HIV business department, visited the People's Network for a live interview to share the current situation and innovative direction of AIDS prevention and treatment.
the end of October 2019, 958,000 people living with HIV were reported nationwide, according to data released by the CDC, and the overall epidemic continued to be at a low epidemic level.
most of the infected patients in China are receiving effective antiviral treatment, and the survival time of patients is also increasing.
," Mr Wang said.
For AIDS two-drug therapy, Wang Hui introduced, HIV antiviral treatment has experienced many twists and turns, from the beginning only the backbone of drugs, to the back by the backbone of drugs and core drugs composed of "cocktail therapy", the current treatment program is moving towards a safer, simpler, better efficacy in the direction.
" there are clinical options that rely on two drugs to achieve the effects of three antiviral drugs.
advantage of this option is that patients take fewer medications and have minimal physical damage.
" Wang Hui pointed out that the current simplified treatment in the clinical, in the real world has achieved better results, Europe and the United States and other countries have also included it in the antiviral treatment program.
Xu Ding, GSK has been introducing new treatment programs for people living with HIV in China since 1999, and so far GSK has successfully registered eight drugs for HIV treatment with the State Drug Administration in China.
AIDS is a major public health issue for China and the world, and the field of the disease is one of GSK's global research and development strategies.
we are committed to continuous research and development of innovative drugs, breakthrough existing treatment options, to promote the development of AIDS prevention and treatment.
we are also actively introducing new drugs in China to improve drug access and promote the inclusion of new treatment options in national health insurance programmes.
" HIV virus had just been discovered and spread, because of its lethality, people were very afraid of the disease.
in fact, in the past two decades, from the "cocktail therapy" applied to the clinical, AIDS survival rate has been effectively improved.
Xu Ding pointed out that the diagnosis and treatment of HIV has changed a lot, patients under scientific treatment, normal life expectancy can be almost the same as normal people.
But as the drug ages older and older, other problems inevitably arise in the body, so pay attention to the interaction between multiple drugs and try to simplify treatment options to achieve better results with fewer drugs.
" from the simplification of the program, we put forward in China to prepare for approval of the two-drug program, previously three or four drugs, now into a double-drug has been a great progress.
from a long-term point of view, we mainly hope to pass the needle way to achieve long-term effect.
" Xu Ding, GSK currently has a once-a-month needle approved for sale in Canada, but also to be approved once-a-month needle treatment program.
" GSK is developing a long-acting two-drug needle program that will allow patients to control HIV with only six injections a year in the near future.
hope that this solution can be better and earlier to the vast number of patients in China.
," Mr Xu said.
Talking about aids patients group care and AIDS prevention and control, Xu Ding said that GSK and the government, medical institutions, industry associations and other active cooperation, through various initiatives to strengthen the public awareness of AIDS, joint public welfare organizations to strengthen the care and support of AIDS patients.
, in-depth grass-roots AIDS diagnosis and treatment training, popularize new treatment programs, improve the level of doctors at all levels.